Clinical Trials Logo
  1. Home
  2. Leukemia, Myeloid, Chronic
  3. NCT00538447
  4. Details
NCT00538447 Clinical Trial

Prospective Database for Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00538447
Other study ID # RAC #2051-056
Secondary ID
Status Active, not recruiting
Phase N/A
First received October 1, 2007
Last updated December 11, 2011
Start date June 2007
Est. completion date June 2020

Study information
Verified date December 2011
Source King Faisal Specialist Hospital & Research Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Prospective Database for Chronic Myelogenous Leukemia

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 2000
Est. completion date June 2020
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with CML

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

Intervention

Other:
• Database
data base for CML

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
King Faisal Specialist Hospital & Research Center

Outcome
Type Measure Description Time frame Safety issue
Primary safety and efficacy 10 years No
See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Completed NCT00759837 - Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Phase 1
Completed NCT00538109 - An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase N/A
Completed NCT00040105 - Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Recruiting NCT01015742 - Unrelated Double Umbilical Cord Blood Units Transplantation Phase 2/Phase 3
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Completed NCT00246662 - Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Phase 1
Completed NCT00264160 - Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy Phase 2/Phase 3
Terminated NCT00306332 - T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation Phase 3
Terminated NCT00058747 - AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ Phase 2
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Completed NCT00034684 - Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) Phase 1/Phase 2
Recruiting NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Phase 1
Terminated NCT00167180 - Post Transplant Donor Lymphocyte Infusion Phase 2
Terminated NCT00449761 - Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase Phase 2
Completed NCT00455221 - Safety Assessment of a Multipeptide-gene Vaccine in CML Phase 1
Completed NCT00298987 - A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate Phase 2
Completed NCT00763763 - Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive Phase 2